secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001493152-24-011612
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma reports FY2023 net loss of $18.0M; pipeline progress on influenza and COVID-19 programs
--------------------------------------------------------------------------------

- Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.
- Cash at Dec 31, 2023: $26.4M, down from $37.1M; net cash used in ops $14.7M.
- FDA provided Pre-IND feedback clarifying requirements for Phase 2b trial of oral CC-42344 for influenza A.
- Expect topline data in 2024 from Phase 2a human challenge study with CC-42344 and Phase 1 study with CDI-988.
- Plan to initiate Phase 1 study of inhaled CC-42344 in 2024 as influenza treatment/prophylactic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224011612/0001493152-24-011612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224011612/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer